

1 Article

2 **2DE-Pattern: A Database for Inventory of Human** 3 **Proteoforms**

4 **Stanislav Naryzhny^{1,2*}, Nikolay Klopov², Natalia Ronzhina², Elena Zorina¹, Victor Zgoda¹, Olga**
5 **Kleyst², Natalia Belyakova², Olga Legina²**

6 ¹ Orekhovich Institute of Biomedical Chemistry of Russian Academy of Medical Sciences, Pogodinskaya 10,
7 Moscow, 119121, Russia

8 ² B.P. Konstantinov Petersburg Nuclear Physics Institute, National Research Center "Kurchatov Institute",
9 Orlova roshcha, Gatchina, Leningrad region, 188300, Russia

10
11 * snaryzhny@mail.ru; Tel.: (+7) 9111764453

12

13 **Abstract:** The human proteome is composed from diverse and heterogeneous gene
14 products/proteoforms. Previously, we have been discussing the main technical aspects in
15 developing for inventory of human proteoforms that would be visually attractive, clear, and easy
16 to search (Naryzhny S. J. Proteomics 2018, S1874-3919(18) 30220-3). Here, we present our first draft
17 of the database of proteoforms that is based on this discussion. The database principles and structure
18 are described. The database is called "2DE-pattern" as it contains multiple isoform-centric patterns
19 of proteoforms separated according to 2DE principles.

20 **Keywords:** proteoforms; database; bioinformatics; pattern; 2DE

21 **1. Introduction**

22 Detailed information about all human proteins is a main target of the Human Proteome
23 Organization (HUPO). Until now, the main efforts of scientific community were pointed to finding
24 the proteins coded by the corresponding genes. This task is close to completion now as from the list
25 of 20199 predicted proteins only ~2000 proteins remain as so-called "missing proteins" and attract
26 the special attention of C-HPP community. But the situation is much more complicated as proteins
27 coded by the same gene can exist in different forms [1–3]. There are different processes generating
28 these forms. Some of them are using genetic variations at mRNA level, such as alternative splicing,
29 different promoters and translation initiation sites. These protein forms are called "isoforms".
30 Additionally, these isoforms can be further chemically modified by post-translational modifications
31 (PTM). The final protein products are called "proteoforms" [3,4]. Because of different combinations
32 of these events, theoretically human proteome could encompass billions of proteoforms [5–8]. Under
33 the same protein name, multiple proteoforms that fulfill different functions can exist. Accordingly,
34 there is a need for a comprehensive inventory of this variety. Proteomics goes deeper and deeper into
35 heterogeneity of proteins; volume of information grows very fast, so there is high demand in
36 convenient ways to use this information. Because of huge amount of data generated, protein
37 databases are a crucial part of proteomics. Indeed, search of sequences databases is a first step in
38 proteomics based on mass spectrometry. In addition, multiple additional databases were developed
39 and are available. The well-known databases are in the National Center for Biotechnology
40 Information (NCBI; <http://www.ncbi.nlm.nih.gov>) and SIB Bioinformatics Resource Portal ExPASy,
41 <https://www.expasy.org/>. Some of them are NeXtProt, UniProt, SWISS-2DPAGE
42 (<https://www.nextprot.org/>, <http://www.uniprot.org/>, [https://world-2dpagexpasy.org/swiss-](https://world-2dpagexpasy.org/swiss-2dpag/)
43 [2dpag/](https://world-2dpagexpasy.org/swiss-2dpag/)) [9–11]. Usually the databases are based on the specific method by which the data were
44 generated. The separation method that ideally suit for proteome analysis is two-dimensional gel
45 electrophoresis (2DE). Because of parameters that are used in this method it fits very well for the
46 database development. Accordingly, multiple 2DE-based protein databases for different objects

47 including human samples, where bottom-up mass spectrometry is widely used, were built, [12]. Now
48 it became evident that for complete characterization of proteoforms top-down mass spectrometry is
49 necessary. So, a proteomics project, where top-down mass-spectrometry was used, was initiated [13].
50 Inside this project, a proteoform database (proteoform atlas) <http://atlas.topdownproteomics.org>,
51 was organized [13,14]. It makes sense to combine all information flows obtained by these and other
52 approaches. As we generated a body of information about proteoforms that is conveniently
53 organized in a graphical way we decided to build a database, where this information can be kept and
54 used by scientific society.

55 2. Materials and Methods

56 2.1. Sample preparation

57 Human glioblastoma cells (a primary line L of glial tumor origin, developed in the laboratory of
58 cell biology, PNPI) were cultured in DMEM or RPMI-1640 medium containing 5% fetal calf serum in
59 5% CO₂ at 37°C without antibiotics [15–16]. Samples were prepared as described previously [17].
60 Cells (~10⁷) containing 2 mg of protein were treated by 100 µL of lysis buffer (7 M urea, 2 M thiourea,
61 4% CHAPS, 1% dithiothreitol (DTT), 2% ampholytes, pH 3-10, protease inhibitors mixture). The
62 protein concentration in the sample was determined by the method of Bradford [18].

63 2.2. 2DE

64 2DE was performed using immobilized pH gradient (IPG) for isoelectric focusing (IEF) [19].
65 After IEF, strips (7 or 24 cm) were soaked 10 min in the equilibration solution (50 mM Tris, pH 8.8, 6
66 M urea, 2% sodium dodecyl sulfate (SDS), 30% (v/v) glycerol, 1% DTT). This process was followed
67 by 10-min incubation in the equilibration solution containing 5% iodoacetamide (IAM) instead of
68 DTT. The strips were placed on the top of the 12% polyacrylamide gel of the second direction and
69 sealed with a hot solution of 1 mL of 0.5% agarose prepared in electrode buffer (25mM Tris, pH 8.3,
70 200 mM glycine, and 0.1% SDS) and electrophoresed to second direction under denaturing conditions
71 using the system Ettan DALTsix (240 × 200 × 1 mm) or Hoefer miniVE (80 × 90 × 1 mm) (GE
72 Healthcare, Pittsburgh, PA, USA). Electrophoresis was carried out at room temperature at constant
73 power 3.5 W per gel [16,20]. Gels were stained with Coomassie Blue R350, scanned by ImageScanner
74 III (GE Healthcare), and analyzed using ImageMaster 2D Platinum 7.0 (GE Healthcare). In case of a
75 sectional 2DE, the gel (8 × 8 cm) was divided into 96 sections with determined coordinates identified
76 as 1-12 along the Mw dimension and A-H – along the pI dimension. All procedures were performed
77 according to the protocol described previously [20]. Each section (~0.7 cm²) was cut, shredded, and
78 treated by trypsin according to the protocol for single spots identification with proportionally
79 increased volumes of solutions. Tryptic peptides were eluted from the gel with extraction solution
80 (5% (v/v) ACN, 5% (v/v) formic acid) and dried in a vacuum centrifuge Speed Vac. Peptides were
81 dissolved in 5% (v/v) formic acid. In case of a semi-virtual 2DE [21], a 24 cm IPG strip was cut into 48
82 equal sections (2 mm), and each section was transferred to Eppendorf tube. For complete reduction,
83 300 µL of 3 mM DTT, 100 mM ABC was added to each sample and incubated at 50°C for 15 min. For
84 alkylation, 20 µL of 100 mM IAM were added to the same tube and incubated in the dark at room
85 temperature for 15 min. For digestion, stock solution of trypsin (0.1 mg/mL) was diluted 1:10 by 25
86 mM ABC, and 100 µL of diluted trypsin was added into each tube. Samples were incubated overnight
87 for 4-24 h at 37°C. Supernatants that may contain peptides that have diffused out of the gel slices
88 were collected to new labeled 0.5 mL tubes. Peptides were extracted by adding 150 µL of 60% ACN,
89 0.1% trifluoroacetic acid (TFA) to each tube containing gel slices. Extracts were dried in Speed Vac,
90 reconstituted in 20 µL of 0.1% TFA, and analyzed by mass spectrometry.

91

92 2.3. MALDI MS and ESI LC-MS/MS analysis

93 All procedures were performed according to the protocol described previously [17,22,23].
94 MALDI TOF mass spectrometry was performed using Microflex MALDI/TOF (Bruker Inc, Bremen,
95 Germany). Tandem mass spectrometry analysis was carried out on an Orbitrap Q-Exactive mass
96 spectrometer (Thermo Scientific, Waltham, MA, USA) according to the protocols described
97 previously [24].

98 2.4. Protein identification

99 Identification of proteins was performed using Mascot "2.4.1" (Matrix Science, London, UK) by
100 searching UniProt/Swiss-Protein sequence database (October 2014, 20196 total sequences). The
101 following search parameters were used: trypsin – as the cutting enzyme, mass tolerance for the
102 monoisotopic peptide window was set to ± 50 ppm, missed cleavages - 1. Cysteine carbamidomethyl
103 was chosen as a fixed modification. A combination of three variable modifications (acetylation of
104 lysine, acetylation of N-end, phosphorylation of serine/threonine or tyrosine, oxidation of
105 methionine) was used. NeXtProt database was used as a protein sequence database. For FDR
106 assessment, a separate decoy database was generated from the protein sequence database. False
107 positive rate of 1% was allowed for protein identification. A minimum Mascot ion score of 30 was
108 used for accepting peptide MS/MS spectra. Data were also searched, using the SearchGUI, an open-
109 source graphical user interface [25]. Two unique peptides per protein were required for all protein
110 identifications. Exponentially modified PAI (emPAI), the exponential form of protein abundance
111 index (PAI) defined as the number of identified peptides divided by the number of theoretically
112 observable tryptic peptides for each protein, was used to estimate protein abundance [26]. All
113 additional information about the methods can be also reached through the front page of the database
114 by clicking the corresponding links for protocols or articles.

115 3. Results


116 3.1. Overview of the database

117 Our main goal is to construct the proteoform database based on 2DE principles. This database
118 should provide a comprehensive and simple tool to keep and share information about human
119 proteoforms with the scientific community. As each proteoform is a unique molecule (polypeptide),
120 a central point in our strategy is usage of such specific polypeptide parameters as isoelectric point
121 (pI) and molecular weight (Mw). Combination of these physicochemical parameters gives a
122 convenient representation of each polypeptide. It is very felicitous that in the classical 2DE separation
123 is performed exactly according to these parameters. It is logical that the SWISS-2DPAGE database
124 that based on these parameters was developed [9,10]. Because of high popularity of 2DE, the SWISS-
125 2DPAGE became a part of the federated 2-D PAGE database [28]. Following in many aspects the
126 organization style of this database we have constructed our human proteoform database. Compare
127 to the SWISS-2DPAGE database this database has some additions. To obtain information about
128 proteoforms, we are using three different approaches based on 2DE separation and identification by
129 mass-spectrometry. First approach is based on a classical 2DE, which is mainly performed according
130 to rules used in the SWISS-2DPAGE and the federated 2DE database [27]. Second one is a sectional
131 2DE, when a whole gel not only selected spots is analyzed by ESI LC-MS/MS section by section. Third
132 one – a semi-virtual 2DE, when proteoforms are separated only by IEF according to their pI. Each
133 approach allows to produce a specific proteoform pattern for every isoform. All three approaches
134 have limitations, but they are complementary each other and allow to obtain better view of the
135 combine proteoform profiles of isoforms.

136 3.2. Database content and search features

137 Our laboratories have expertise in proteomics by analysis of proteins and proteoforms using
138 2DE and mass spectrometry (MALDI TOF and ESI LC-MS/MS) [28]. We are using different samples,

139 and information about proteoform patterns obtained from experiments performed with these
140 samples is included into the database. Each entry in the database corresponds to one protein isoform
141 and contains a textual as well as a graphical data. Every search starts from the front page (Figure 1),
142 where four different protein search options are offered: 1 – UniProt accession number of the protein,
143 2 – name of the protein, 3 – name of the gene, 4 – graphical interface (2DE map). Also, in the front
144 page, user can find links to the methods and papers that contain information that was included into
145 the database. Depending on the choice taken, it will be one- or two-step transition to the protein page
146 (Figure 2), where the basic information about the protein is presented. The ID (identification) and the
147 AC (accession number) are the same as the corresponding sequence entry in SWISS-PROT. The
148 description line contains general information about the protein. The page also contains a subset links
149 to protein portals such as protein atlas, UniProt, NeXtProt. Also, accession numbers and names of
150 all known isoforms for this protein are presented here. By clicking on the isoform accession number,
151 user is transferred to the page of this isoform (an isoform page) (Figure 3). Isoform page has links to
152 the pages of different samples with information about this isoform (a sample pages). By clicking on
153 the corresponding link, user can go to the sample page and obtain the proteoform pattern that is
154 produced by each of these approaches. In the first draft of our database, there is only one sample –
155 glioblastoma cells [29]. There is also a link in the sample name, where available information about
156 detected isoforms is presented as a table. More samples, such as normal and cancer cells
157 (hepatoblastoma carcinoma (HepG2), lung fibroblasts (LEH), HeLa, HEK) and tissues (liver, blood
158 plasma) will be incorporated soon.



160

Figure 1. The front page of the human proteoform database “2DE pattern”.

General information about the entry	
Protein	ATPA
Gene	ATP5F1A
Primary accession number	P25705
Protein name	ATP synthase subunit alpha, mitochondrial
Function	Mitochondrial membrane ATP synthase (F ₁ F ₀) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain...
Chromosome	18
Isoform accession number	(P25705-1(isoform 1)) Get links
	(P25705-3(isoform 3))
	(P25705-2(isoform 2))

161

162

163

Figure 2. A protein page of the human proteoform database “2DE pattern”. Main information about ATP synthase subunit alpha (ATPA) is shown. Beneath, a choice of isoform is available.

164

165

166

167

Figure 3. An isoform page of the human proteoform database “2DE pattern”. A selection of three types of the 2DE pattern for the isoform 1 of ATPA (P25705-1) is presented (2DE, sectional 2DE, or semi-virtual 2DE).

168

169

170

171

172

173

174

175


176

177

178

179

There are three types of a sample page. In a first type (2DE), user can find a proteoform pattern of the isoform that is obtained by a classical 2DE (Figure 4A). This pattern is presented in a page that is organized based on the same principles as the SWISS-2DPAGE database and the federated 2DE database: <http://world-2dpagexpasy.org/>. In a 2DE map, spots, where different proteoforms of the same isoform were detected, are highlighted. Accordingly, a proteoform pattern of this isoform is produced. Additionally, basic experimental information about the spot abundance and the isoform (isoform name, protein name, gene name, chromosome, theoretical pI, theoretical Mw, experimental pI, theoretical Mw, emPAI, modifications) is shown. Minimal information obtained by mass spectrometric analysis is shown in the table. Also, by clicking on a spot user can extract information about all isoforms that were detected in this spot. For to-day, we have analyzed 700 spots and identified 703 different isoforms.



180

181

182

183

Figure 4A. A sample page of the human proteoform database “2DE pattern”, where a classical 2DE is used. All spots, where isoforms were detected are marked by green. Information about each spot is presented in a table. Spots with proteoforms of the isoform 1 of ATPA (P25705-1) are shown by red.

184


185

186

187

188

A second type of a sample page – a page, where a pattern is extracted from the sectional 2DE [20] (Figure 4B). Here, two images are presented – a whole image of 2DE with sections and a graph showing distribution of specific proteoforms around these sections. Additionally, in a similar way as in the first type of a sample page the detailed information about the isoform and its proteoforms is presented in the Tables. For to-day, we have data for 3472 isoforms.



189

190

191

Figure 4B. A sample page of the human proteoform database “2DE pattern”, where a sectional 2DE is used. Proteoform pattern of the isoform 1 of ATPA (P25705-1) is shown.

192

193

194

195

Third type of a sample page – a page, where pattern of the isoform is produced by semi-virtual 2DE (Figure 4C). Here on the left, a semi-virtual 2DE of proteoforms of the most abundant cellular proteins is presented. On the right – a proteoform pattern of the isoform. Inside the graph, proteoforms are represented proportionally (according to emPAI) by balls. Also, available information about the

196 isoform and detected proteoforms is presented in the tables. At this moment, such patterns are
197 available for 3549 isoforms.



198

199 **Figure 4C.** A sample page of the human proteoform database “2DE pattern”, where a semi-virtual 2DE is used.
200 Proteoform pattern of the isoform 1 of ATPA (P25705-1) is shown.

201 What is important, in all these sample pages, user can go over to Uniprot or Proteoform atlas. In
202 UniProt, available information about post-translation modifications (PTM) of the isoform can be
203 found. In Proteoform atlas, it is possible for some cases to find proteoforms that have been already
204 detected by top-down mass spectrometry. Collecting all these data together will allow to draw a final
205 proteoform pattern.

206 4. Discussion

207 At the moment, our database doesn't have the substantial body of information about PTM that
208 are responsible for the variety of observed proteoforms (patterns). The database needs more specific
209 information about PTM of proteoforms. We have plans to include this information into the database
210 gradually after more detailed MS data analysis. The website currently presents information about
211 glioblastoma proteins only. More information using other samples (proteins from FLEH, HepG2,
212 HEK, HeLa, liver, and plasma) will be included into the database as a next step.

213 5. Conclusions

214 This work describes the database “2DE-pattern” that was developed for keeping and sharing
215 information about patterns or profiles of human proteoforms. These patterns were generated by
216 separation of proteoforms, identification them by mass spectrometry, and constructing of multiple
217 graphs, where proteoforms of the same isoform are presented. Separation was performed according
218 to pI/Mw parameters using three variations of a classical 2DE. Accordingly, it can be up to three
219 different proteoform profiles for each protein isoform entry in the database. All these patterns are
220 complementary each other and allow to come closer to the complete set of proteoforms. In some cases,
221 information about PTM of these proteoforms that was obtained from MS data is available.
222 Additionally, based on pI/Mw parameters it is possible to have a hint whether a proteoform has any
223 PTM or not. It is important to point out that usually in the most abundant proteoforms theoretical
224 and experimental pI/Mw parameters are very similar showing that these proteoforms mostly likely
225 are not modified. All types of a shift (left, right, up, down) are a result of different types of PTM. So,

226 depending on the shift direction we can propose, which kind of PTM was happened. More detailed
227 data can be also found by clicking the links to UniProt database. Using the available information,
228 user will have a chance to construct a more detailed image of the proteoform pattern. We can expect
229 this ideal situation only in future as right now Proteoform atlas has data only about 9,694 proteoforms
230 detected in all human cells. According to the modest evaluations just a single human cell has at least
231 70000 proteoforms and a human proteome could encompass billions of proteoforms [5–8].

232 The database is freely available at <http://www.2de-pattern.pnpi.nrcki.ru>

233

234 **Author Contributions:** conceptualization, supervision, writing—review and editing, Stanislav Naryzhny;
235 software, data curation, resources, Nikolay Klopov; formal analysis, data curation, Natalia Ronzhina; formal
236 analysis, data curation, Elena Zorina; formal analysis, data curation, Victor Zgoda; data curation, Olga Kleyst;
237 data curation, Natalia Belyakova; data curation, Olga Legina.

238 **Acknowledgments:** The data was obtained under the Program of Fundamental Research of State Academies of
239 Sciences for 2013-2020. Mass-spectrometry measurements were performed using the equipment of “Human
240 Proteome” Core Facilities of the Institute of Biomedical Chemistry (Russia).

241 **Conflicts of Interest:** The authors declare no conflict of interest.

242 Abbreviations

243 The following abbreviations are used in this manuscript:

244	2DE	two-dimensional electrophoresis
245	ESI LC-MS/MS	liquid chromatography-electrospray ionization-tandem mass spectrometry
246	ABC	ammonium bicarbonate
247	ACN	acetonitrile
248	MS	mass spectrometry
249	PTM	post-translation modifications
250	emPAI	exponential modified form of protein abundance index

251

252 References

- 253 1. Schlüter H.; Apweiler R.; Holzhütter H-G.; Jungblut P.R. Finding one's way in proteomics: a protein species
 254 nomenclature. *Chem Cent J*. **2009**, *3*, 11.
- 255 2. Jungblut P.; Thiede B.; Zimny-Arndt U.; Muller E.C.; Scheler C.; Wittmann-Liebold B.; Otto A. Resolution
 256 power of two-dimensional electrophoresis and identification of proteins from gels. *Electrophoresis*. **1996**,
 257 *17*, 839–47.
- 258 3. Smith L.M.; Kelleher N.L. Proteoform: A single term describing protein complexity. *Nature Methods*. **2013**,
 259 *10*, 186–7.
- 260 4. Smith L.M.; Kelleher N.L. Proteoforms as the next proteomics currency. *Science (80-)*. **2018**, *359*, 1106–7.
- 261 5. Kelleher N.L. A cell-based approach to the human proteome project. *J Am Soc Mass Spectrom*. **2012**, *23*,
 262 617–24.
- 263 6. Jungblut P.R. The proteomics quantification dilemma. *J Proteomics*. **2014**, *107*, 98–102.
- 264 7. Naryzhny S.N.; Lisitsa A.V.; Zgoda V.G.; Ponomarenko E.A.; Archakov A.I. 2DE-based approach for
 265 estimation of number of protein species in a cell. *Electrophoresis*. **2014**, *35*, 895–900.
- 266 8. Naryzhny S.N.; Zgoda V.G.; Maynskova M.A.; Ronzhina N.L.; Belyakova N.V.; Legina O.K.; Archakov A.I.
 267 [Experimental estimation of proteome size for cells and human plasma]. *Biomed Khim*. **2015**, *61*, 279–85.
- 268 9. Gasteiger E.; Gattiker A.; Hoogland C.; Ivanyi I.; Appel R.D.; Bairoch A. ExPASy: The proteomics server
 269 for in-depth protein knowledge and analysis. *Nucleic Acids Res*. **2003**, *31*, 3784–8.
- 270 10. Hoogland C.; Sanchez J.C.; Walther D.; Baujard V.; Baujard O.; Tonella L.; Hochstrasser D.F.; Appel, R.D.
 271 Two-dimensional electrophoresis resources available from ExPASy. *Electrophoresis*. **1999**, *20*, 3568–3571.
- 272 11. Lane L.; Argoud-Puy G.; Britan A.; Cusin I.; Duek P.D.; Evalet O.; Gateau A.; Gaudet P.; Gleizes A.;
 273 Masselot A.; Zwahlen C.; Bairoch A. NeXtProt: A knowledge platform for human proteins. *Nucleic Acids*
 274 *Res*. **2012**, *D76*–83.
- 275 12. Hoogland C.; Mostaguir K.; Appel R.D.; Lisacek F. The World-2DPAGE Constellation to promote and
 276 publish gel-based proteomics data through the ExPASy server. *J Proteomics*. **2008** *71*, 245–8.
- 277 13. Toby T.K.; Fornelli L.; Kelleher N.L. Progress in Top-Down Proteomics and the Analysis of Proteoforms.
 278 *Annu Rev Anal Chem (Palo Alto Calif)*. **2016**, *9*, 499–519.
- 279 14. Leduc R.D.; Schwämmle V.; Shortreed M.R.; Cesnik A.J.; Solntsev S.K.; Shaw J.B.; Martin M.J.; Vizcaino
 280 J.A.; Alpi E.; Danis P.; Kelleher N.L.; Smith L.M.; Ge Y.; Agar J.N.; Chamot-Rooke J.; Loo J.A.; Pasa-Tolic L.;
 281 Tsybin Y.O. ProForma: A Standard Proteoform Notation. *J Proteome Res*. **2018**, *17*, 1321–1325.
- 282 15. Naryzhny S.N.; Ronzhina N.L.; Mainskova M.A.; Belyakova N.V.; Pantina R.A.; Filatov M.V. Development
 283 of barcode and proteome profiling of glioblastoma. *Biochem Suppl Ser B Biomed Chem*. **2014**, *8*, 243–251.
- 284 16. Shtam T.A.; Naryzhny S.N.; Landa S.B.; Burdakov V.S.; Artamonova T.O.; Filatov M.V. Purification and in
 285 vitro analysis of exosomes secreted by malignantly transformed human cells. *Cell tissue biol*. **2012**, *6*, 317–
 286 325.
- 287 17. Naryzhny S.N. Blue Dry Western: Simple, economic, informative, and fast way of immunodetection. *Anal*
 288 *Biochem*. **2009**, *392*, 90–5.
- 289 18. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities utilizing the
 290 principle of protein-dye binding. *Anal Biochem*. **1976**, *72*, 248–54.

- 291 19. Gorg A.; Postel W.; Domscheit A.; Gunther S. Two-dimensional electrophoresis with immobilized pH
292 gradients of leaf proteins from barley (*Hordeum vulgare*): method, reproducibility and genetic aspects.
293 *Electrophoresis*. **1988**, *9*, 681–92.
- 294 20. Naryzhny S.N.; Zgoda V.G.; Maynskova M.A.; Novikova S.E.; Ronzhina N.L.; Vakhrushev I. V.; Archakov
295 A.I. Combination of virtual and experimental 2DE together with ESI LC-MS/MS gives a clearer view about
296 proteomes of human cells and plasma. *Electrophoresis*. **2016**, *37*, 302–9.
- 297 21. Naryzhny S.; Zgoda V.; Kopylov A.; Petrenko E.; Archakov A. A semi-virtual two dimensional gel
298 electrophoresis: IF-ESI LC-MS/MS. *MethodsX*. **2017**, *4*, 260–4.
- 299 22. Naryzhny S.N.; Lee H. Characterization of proliferating cell nuclear antigen (PCNA) isoforms in normal
300 and cancer cells: There is no cancer-associated form of PCNA. *FEBS Lett*. **2007**, *581*, 4917-20.
- 301 23. Naryzhny S.N.; Maynskova M.A.; Zgoda V.G.; Ronzhina N.L.; Kleyst O.A.; Vakhrushev I.V.; Archakov A.I.
302 Virtual-Experimental 2DE Approach in Chromosome-Centric Human Proteome Project. *J Proteome Res*.
303 **2016**, *15*, 525-30.
- 304 24. Zgoda V.G.; Moshkovskii S.A.; Ponomarenko E.A.; Andreewski T.V.; Kopylov A.T.; Tikhonova O.V.;
305 Melnik S.; Lisitsa A.V.; Archakov A.I. Proteomics of mouse liver microsomes: Performance of different
306 protein separation workflows for LC-MS/MS. *Proteomics*. 2009, *9*, 4102-5.
- 307 25. Vaudel M.; Barsnes H.; Berven F.S.; Sickmann A.; Martens L. SearchGUI: An open-source graphical user
308 interface for simultaneous OMSSA and X!Tandem searches. *Proteomics*. **2011**, *11*, 996–9.
- 309 26. Ishihama Y.; Oda Y.; Tabata T.; Sato T.; Nagasu T.; Rappsilber J.; Mann M. Exponentially Modified Protein
310 Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of
311 Sequenced Peptides per Protein. *Mol Cell Proteomics*. **2005**, *4*, 1265–72.
- 312 27. Appel R.D.; Bairoch A.; Sanchez J.C.; Vargas J.R.; Golaz O.; Pasquali C.; Hochstrasser D.F. Federated two-
313 dimensional electrophoresis database: A simple means of publishing two-dimensional electrophoresis
314 data. *Electrophoresis*. **1996**, *17*, 540–6.
- 315 28. Naryzhny S. Towards the Full Realization of 2DE Power. *Proteomes*. **2016**, *4*, 33.
- 316 29. Naryzhny S.N.; Maynskova M.A.; Zgoda V.G.; Ronzhina N.L.; Novikova S.E.; Belyakova N.V.; Kleyst O.A.;
317 Legina O.K.; Pantina R.A.; Filatov M.V. Proteomic Profiling of High-grade Glioblastoma Using Virtual
318 experimental 2DE. *J Proteomics Bioinform*. **2016**, *9*, 158-165.
319